Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

87.74EUR
26 May 2017
Change (% chg)

€0.43 (+0.49%)
Prev Close
€87.31
Open
€87.43
Day's High
€88.13
Day's Low
€87.04
Volume
2,239,910
Avg. Vol
2,384,369
52-wk High
€92.97
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €109,996.80
Shares Outstanding(Mil.): 1,259.84
Dividend: 2.96
Yield (%): 3.39

Financials

  SASY.PA Industry Sector
P/E (TTM): 24.05 14.31 17.43
EPS (TTM): 3.63 -- --
ROI: -- -7.26 -5.41
ROE: -- -6.76 -4.69

UPDATE 1-Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

May 22 The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.

May 22 2017

Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.

May 22 2017

Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

May 22 The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.

May 22 2017

BRIEF-Regeneron, Sanofi RA drug wins FDA nod; co's price it at $39,000/patient/yr

* Regeneron and sanofi announce fda approval of kevzara® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients

May 22 2017

BRIEF-Sanofi receives CHMP recommendation for approval of insulin lispro biosimilar

* REG-SANOFI RECEIVES CHMP RECOMMENDATION FOR APPROVAL OF INSULIN LISPRO BIOSIMILAR

May 19 2017

Sanofi says has no "absolute need" to do acquisitions

PARIS Sanofi is currently looking at several external growth opportunities, after having failed to clinch two large deals recently, but feels it has no urgent need to make acquisitions, the drugmaker's chairman told shareholders on Wednesday.

May 10 2017

Sanofi says has no 'absolute need' to do acquisitions

PARIS Sanofi is currently looking at several external growth opportunities, after having failed to clinch two large deals recently, but feels it has no urgent need to make acquisitions, the drugmaker's chairman told shareholders on Wednesday.

May 10 2017

UPDATE 1-Sanofi says has no "absolute need" to do acquisitions

PARIS, May 10 Sanofi is currently looking at several external growth opportunities, after having failed to clinch two large deals recently, but feels it has no urgent need to make acquisitions, the drugmaker's chairman told shareholders on Wednesday.

May 10 2017

Sanofi says has no "absolute need" to do acquisitions

PARIS, May 10 Sanofi is currently looking at several external growth opportunities, after having failed to clinch two large deals recently, but feels it has no urgent need to make acquisitions, the drugmaker's chairman told shareholders on Wednesday.

May 10 2017

Sanofi pegs U.S. drug price rises to below healthcare inflation

French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances.

May 09 2017

More From Around the Web

Earnings vs. Estimates